作为CXCL13预测生物标志物,用于对风湿性关节炎中甲甲酸单一治疗的反应
Vishnu S Chandran1,2, Mithun C B1, Sajitha Krishnan3
1Department of Rheumatology and Clinical Immunology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, India.
概括
较高的基线CXCL13水平预测了早期类风湿性关节炎 (RA) 中的甲状腺素反应. 治疗后CXCL13的下降表明治疗成功,这表明它有可能成为RA管理的生物标志物.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 早期类风湿性关节炎 (RA) 管理需要有效预测治疗反应.
- 甲托雷克萨特是一种常见的第一线治疗RA.
- 识别可靠的生物标志物以指导甲醇治疗至关重要.
研究的目的:
- 为了研究基线CXCL13水平在预测早期RA患者中甲状腺的反应中的有用性.
- 评估CXCL13在甲状腺治疗期间监测疾病活动中的作用.
- 评估CXCL13作为个性化RA治疗策略的潜在生物标志物.
主要方法:
- 对50名未经治疗的早期RA患者进行前性研究.
- 在12周时分类为甲状腺素反应者 (MTX-R) 和不反应者 (MTX-NR).
- 基线和治疗后CXCL13水平的分析以及与疾病活性评分的相关性 (DAS-28).
主要成果:
- 与MTX-NR相比,MTX-R观察到显著更高的CXCL13基线水平 (P = 0.035).
- 基线CXCL13切断值>100 pg/mL预测了62%的准确性对甲状腺素的反应.
- 在MTX-R治疗后,CXCL13水平显著下降 (P<0.001),但在MTX-NR中保持不变.
结论:
- 基线CXCL13水平可能有助于分层早期的RA患者,可能对甲状腺酸盐有反应.
- 治疗后CXCL13的减少与临床改善相关,支持其在监测中的使用.
- CXCL13显示出作为优化个性化RA治疗的辅助生物标志物的潜力,需要进一步验证.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240